Final Berkshire Biomedical Webinar to Spotlight Transformational Potential of COPA™ Across High-Need Conditions
Dallas, Texas, April 18, 2025 (GLOBE NEWSWIRE) — 
As Berkshire Biomedical nears the shut of its fairness crowdfunding marketing campaign on StartEngine, the corporate will host its remaining investor-focused webinar on Thursday, April 24, at 1:30 PM PST. The session will provide a deeper take a look at how Berkshire’s COPA™ (Computerized Oral Prescription Administration) expertise might handle pressing challenges in remedy security, adherence, and misuse throughout a variety of therapeutic classes.
Whereas Berkshire’s preliminary market focus for COPA might be for Medicine for Opioid Use Dysfunction (MOUD), its precision, management, and real-time connectivity could have far-reaching purposes. The upcoming webinar will discover its potential use in treating power ache, ADHD, epilepsy, Alzheimer’s illness, and supporting post-surgical restoration, with a deal with decreasing danger, bettering outcomes, and enabling safe, customized care.
John Timberlake, President and CEO of Berkshire Biomedical, will lead the dialogue alongside Tom King, Senior Advisor to the Firm. The audio system will even study COPA’s potential worth to scientific analysis organizations and pharmaceutical companions as a digital drug supply platform for scientific trials and high-risk drugs.
Attendees will hear how the COPA platform might help sufferers, caregivers, and care groups alike—and the way its integration into scientific and industrial settings might unlock strategic partnerships, licensing, and future institutional development alternatives.
That is the ultimate alternative to have interaction instantly with firm management earlier than Berkshire Biomedical’s StartEngine marketing campaign closes.
About Berkshire Biomedical Company
Berkshire Biomedical Company is a privately held medical gadget firm. Berkshire is pioneering the usage of biometric applied sciences, mixed with encrypted HIPAA-compliant cloud-based and healthcare provider-enabled distant administration methods, to supply exact and correct customized remedy supply to solely the Authenticated Supposed Person (AIU).
The Firm’s lead product beneath improvement, the Computerized Oral Prescription Administration System (COPA), is a hand-held, automated, customized oral liquid shelling out system designed and meant to ship managed and non-controlled liquid oral drugs to solely the AIU upon affirmation of twin biometric identification (fingerprint and dentition).
Upon receiving regulatory authorization, the Firm intends to initially search alternatives to leverage COPA within the supply and distant administration of oral liquid remedy methadone, for Medicine Use for Opioid Use Dysfunction remedy and subsequently for the supply of managed drugs for the remedy of ache, as these sufferers have the best want for the advantages of COPA’s options.
As beforehand introduced, the Firm has developed COPA with the help of a $2.0 million Quick-Monitor Small Enterprise Innovation Analysis grant from the Nationwide Institute on Drug Abuse of the Nationwide Institutes of Well being beneath award quantity R44DA057185.
Sooner or later, the corporate will look to increase COPA utilization right into a broader set of drug therapeutics and doable scientific purposes, in addition to with corporations that make the most of and commercialize information analytics offered by digital gadgets to enhance outcomes and scale back danger.
The COPA System is at present beneath improvement, has NOT been reviewed by the U.S. Meals and Drug Administration, and isn’t accessible for industrial sale.
